INTERVIEW: Widecells Group Plc Maiden Revenues

Widecells Group plc (LON:WDC) CEO Joao Andrade & Non-executive director Dr Marilyn Orcharton, talks to DirectorsTalk about what’s behind CellPlan, what the receipt of the licence means for Widecells, a new route to market and their hopes for the stem cell industry.

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.

With this in mind, it has created three divisions:

·     CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process

·     WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Center to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising in stem cell storage.

Share this interview

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp
WideCells Group
INTERVIEW: Widecells Group Plc Maiden Revenues

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions